about
Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growthAddition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyLymphoma: turning biology into cures.Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease.Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 StudySafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trialEstablishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survivalBreast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses.Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?Stratified medicine for cancer therapy.FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, AND CBF1.The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.
P50
Q24321127-15ACFDC3-E4EC-4BAD-A066-452486A7867FQ28282827-2CE58CA0-70CE-43A8-8C65-474C333200EFQ30240069-B43D84EA-3B15-48B6-A902-A3815FDBF80CQ30279207-F3DA183D-FF8B-40D7-98C6-E3A189FEEAF3Q30873571-D4D5931B-8887-4212-AFD2-ECD90AB112F0Q33237559-EF0E53D4-E1F6-48EC-86A1-E70EE8846811Q33362194-8DEB278B-F271-4D99-A146-56D99B746422Q33364348-36B0D67A-0EC9-4461-9FEA-6021BBD095AAQ33370812-71F0A0D1-498C-4700-9E12-BF76303D33B8Q33385766-DEF077C0-399B-46F9-8CB3-02F4948ACD58Q33405150-680173A0-468D-426E-906C-BDA155C8BAA0Q33407265-479567D8-9375-4B80-A703-06AF0FF7D96FQ33440896-77715DD5-B84F-46E2-B7EA-8CEBE7802227Q33494790-025F0DDA-4858-418F-A452-6C361DBA340CQ33557015-C9B1AB25-54D4-49F5-B367-4D31AD15C43EQ33683176-33BA22B2-A3BF-47EC-BCAB-9C34A88C4E79Q34276522-5B78FEEE-B0EE-49A6-99AC-C88CA7E7ACCEQ34978570-E2A29947-7D24-4173-80C2-3EBC095CA09EQ34978844-884B3026-F3BB-4643-B724-F87B39906695Q36393276-A9896FF3-8581-48FE-838F-7B146B76235AQ36472987-4EA9C206-9124-484C-B8F9-F3794EF068B2Q37024999-F13D2FAD-C747-446B-A0B6-BB87BFDA62FCQ37126978-AA86CE1B-92DF-4803-BE32-B2B105B46925Q37252722-93BB774F-E9DB-4167-980A-C2D71ED9B045Q38001719-8ABB5D68-B366-4823-BAD6-7F64B5AD3A9FQ38094625-5C3A5F0E-5C12-427F-92AD-9BACB0B1A48BQ38108836-B77C4CDD-FC80-4596-BC77-097C0086FA43Q38209637-071B8C42-3B3A-4990-9BCF-6D9EE6B4CFF2Q38309488-EA0A763A-1B59-40BF-A7F3-AD15319946D1Q38396244-36B4DBBB-09D9-4906-8587-D4BF9D40FFF3Q39150343-4DAD6401-F188-416E-B529-7501427CC2EEQ39504804-E9133F8F-BB1B-4E05-8334-05EA783B9EA4Q39691780-C08048AD-0DF6-40AD-BADE-33B358BD48E6Q39939828-3F3C91EB-8171-414E-8341-EA1EF1BBC4C5Q40040274-6F432043-87A4-4D7B-8072-717DB4AA40A7Q40183645-A3BDBA72-2B8C-434F-8177-590602F1340BQ40382943-295EE420-66B1-495F-940F-BADDD202115EQ40560316-3FB3695D-D5BE-4F51-9BD0-BC1D2F92300FQ40745472-09332CF1-55DD-446F-A4E0-1CBC54F9CD02Q40957763-CDA7E123-768F-43CE-8E07-7F41DDA4BCDA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter W Johnson
@ast
Peter W Johnson
@en
Peter W Johnson
@es
Peter W Johnson
@nl
Peter W Johnson
@sl
type
label
Peter W Johnson
@ast
Peter W Johnson
@en
Peter W Johnson
@es
Peter W Johnson
@nl
Peter W Johnson
@sl
altLabel
Peter Johnson
@en
prefLabel
Peter W Johnson
@ast
Peter W Johnson
@en
Peter W Johnson
@es
Peter W Johnson
@nl
Peter W Johnson
@sl
P1053
L-2403-2018
P106
P1153
55619305816
P21
P31
P3829
P496
0000-0003-2306-4974